Aemetis Inc. (NASDAQ:AMTX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The firm currently has a $2.00 target price on the stock. Zacks Investment Research’s target price suggests a potential upside of 9.89% from the company’s previous close.

According to Zacks, “Aemetis, Inc. is an advanced fuels and renewable chemicals company. It produces renewable chemicals and fuels using patented microbes and processes. Aemetis owns and operates an ethanol animal feed plant in California to produce D5 Advanced Biofuels using the sorghum/biogas/CHP pathway. The Company also built, owns, and operates a renewable chemicals and advanced fuels production facility on the East Coast of India producing high quality, distilled biodiesel and refined glycerin for customers in Europe and Asia. Aemetis, Inc. is headquartered in Cupertino, California. “

Separately, FBR & Co set a $2.00 price target on shares of Aemetis and gave the stock a “hold” rating in a research note on Monday.

Shares of Aemetis (NASDAQ:AMTX) opened at 1.82 on Wednesday. The stock has a 50 day moving average price of $1.63 and a 200 day moving average price of $1.88. The firm’s market capitalization is $36.14 million. Aemetis has a 52 week low of $1.01 and a 52 week high of $3.05.

Aemetis (NASDAQ:AMTX) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.06. Equities analysts forecast that Aemetis will post ($1.04) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Aemetis stock. Geneva Advisors LLC raised its stake in Aemetis Inc. (NASDAQ:AMTX) by 4.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,453,131 shares of the company’s stock after buying an additional 68,460 shares during the period. Geneva Advisors LLC owned approximately 7.32% of Aemetis worth $1,569,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 18.57% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Aemetis Inc. (AMTX) Stock Rating Upgraded by Zacks Investment Research” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2016/11/25/aemetis-inc-amtx-stock-rating-upgraded-by-zacks-investment-research.html.

Aemetis Company Profile

Aemetis, Inc is an international renewable fuels and biochemicals company. The Company is focused on the production of fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products by conversion of first-generation ethanol and biodiesel plants into biorefineries.

5 Day Chart for NASDAQ:AMTX

Receive News & Stock Ratings for Aemetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis Inc. and related stocks with our FREE daily email newsletter.